Journal article icon

Journal article

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study

Abstract:

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis. Here we report the final analysis of Oral Psoriatic Arthritis Trial (OPAL) Balance, a 36-month long-term extension study, with a 12-month methotrexate withdrawal substudy, that assessed tofacitinib safety, tolerability, and efficacy in patients with active psoriatic arthritis.

Methods For this open-label, long-term extension study, which was run at 12...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S2665-9913(21)00010-2

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
Lancet Rheumatology Journal website
Volume:
3
Issue:
4
Pages:
e270-e283
Publication date:
2021-03-24
Acceptance date:
2021-01-08
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Language:
English
Keywords:
Pubs id:
1156932
Local pid:
pubs:1156932
Deposit date:
2021-01-18

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP